A coalition of states is seeking approval for a $400 million settlement to resolve allegations that two generic drug manufacturers, Sandoz Inc. and Fougera Pharmaceuticals Inc., engaged in “long-running conspiracies” to inflate drug prices and reduce competition from other companies.
The coalition of states and territories filed a motion for preliminary approval of the settlement with the companies on Oct. 1 in the U.S. District Court for the District of Connecticut in Hartford.
“Conspiring to charge Washington consumers more for the medicines they need is illegal and cruel,” Brown said. “Elected officials must work together to hold drug companies accountable and support consumers.”
Both companies are generic drug manufacturers that make standard versions of many medications.
Consumers who purchased a generic prescription drug between May 2009 and December 2019 may be eligible for compensation. To determine eligibility, call 1-866-290-0182 (Toll-Free), email info@AGGenericDrugs.com, or visit www.AGGenericDrugs.com. Consumers can submit a claim for compensation here.
Along with individual claims, Washington and Idaho have secured restitution for businesses affected by the companies’ unfair practices.
In the statement, Brown said businesses can find out if they are eligible for compensation at https://www.aggenericdrugs.com/English/CorporateEntities.
According to Brown, along with the settlement, Washington is part of a coalition of nearly all states and territories engaged in an ongoing series of antitrust cases over generic drug prices that began in 2016.